Global Recombinant Vector Vaccines Market Growth 2025-2031
The global Recombinant Vector Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
United States market for Recombinant Vector Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Vector Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Vector Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Vector Vaccines players cover SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Vector Vaccines Industry Forecast” looks at past sales and reviews total world Recombinant Vector Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Vector Vaccines sales for 2025 through 2031. With Recombinant Vector Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Vector Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Vector Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Vector Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Vector Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Vector Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Vector Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Vector Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Recombinant Vector Vaccines market?
What factors are driving Recombinant Vector Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Vector Vaccines market opportunities vary by end market size?
How does Recombinant Vector Vaccines break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
United States market for Recombinant Vector Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Vector Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Vector Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Vector Vaccines players cover SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Vector Vaccines Industry Forecast” looks at past sales and reviews total world Recombinant Vector Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Vector Vaccines sales for 2025 through 2031. With Recombinant Vector Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Vector Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Vector Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Vector Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Vector Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Vector Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Vector Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Vector Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Varicella
- Influenza
- Hepatitis
- Pertussis, Diphtheria, tetanus
- Pneumococcal
- Others
- For Adult
- For Child
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- SANOFI PASTEUR S.A.
- Novartis
- GSK
- CNBG
- ChengDa Bio
- Changsheng Life
- Zhifei
- SINOVAC BIOTECH
- NuoCheng Bio
- Hualan Bio
- Kangtai
What is the 10-year outlook for the global Recombinant Vector Vaccines market?
What factors are driving Recombinant Vector Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Vector Vaccines market opportunities vary by end market size?
How does Recombinant Vector Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Vector Vaccines Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Vector Vaccines by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Vector Vaccines by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Vector Vaccines Segment by Type
2.2.1 Varicella
2.2.2 Influenza
2.2.3 Hepatitis
2.2.4 Pertussis, Diphtheria, tetanus
2.2.5 Pneumococcal
2.2.6 Others
2.3 Recombinant Vector Vaccines Sales by Type
2.3.1 Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
2.3.2 Global Recombinant Vector Vaccines Revenue and Market Share by Type (2020-2025)
2.3.3 Global Recombinant Vector Vaccines Sale Price by Type (2020-2025)
2.4 Recombinant Vector Vaccines Segment by Application
2.4.1 For Adult
2.4.2 For Child
2.5 Recombinant Vector Vaccines Sales by Application
2.5.1 Global Recombinant Vector Vaccines Sale Market Share by Application (2020-2025)
2.5.2 Global Recombinant Vector Vaccines Revenue and Market Share by Application (2020-2025)
2.5.3 Global Recombinant Vector Vaccines Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Recombinant Vector Vaccines Breakdown Data by Company
3.1.1 Global Recombinant Vector Vaccines Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Vector Vaccines Sales Market Share by Company (2020-2025)
3.2 Global Recombinant Vector Vaccines Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Vector Vaccines Revenue by Company (2020-2025)
3.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global Recombinant Vector Vaccines Sale Price by Company
3.4 Key Manufacturers Recombinant Vector Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Vector Vaccines Product Location Distribution
3.4.2 Players Recombinant Vector Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RECOMBINANT VECTOR VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Vector Vaccines Market Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Vector Vaccines Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Vector Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Vector Vaccines Market Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Vector Vaccines Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Vector Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Vector Vaccines Sales Growth
4.4 APAC Recombinant Vector Vaccines Sales Growth
4.5 Europe Recombinant Vector Vaccines Sales Growth
4.6 Middle East & Africa Recombinant Vector Vaccines Sales Growth
5 AMERICAS
5.1 Americas Recombinant Vector Vaccines Sales by Country
5.1.1 Americas Recombinant Vector Vaccines Sales by Country (2020-2025)
5.1.2 Americas Recombinant Vector Vaccines Revenue by Country (2020-2025)
5.2 Americas Recombinant Vector Vaccines Sales by Type (2020-2025)
5.3 Americas Recombinant Vector Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Vector Vaccines Sales by Region
6.1.1 APAC Recombinant Vector Vaccines Sales by Region (2020-2025)
6.1.2 APAC Recombinant Vector Vaccines Revenue by Region (2020-2025)
6.2 APAC Recombinant Vector Vaccines Sales by Type (2020-2025)
6.3 APAC Recombinant Vector Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Vector Vaccines by Country
7.1.1 Europe Recombinant Vector Vaccines Sales by Country (2020-2025)
7.1.2 Europe Recombinant Vector Vaccines Revenue by Country (2020-2025)
7.2 Europe Recombinant Vector Vaccines Sales by Type (2020-2025)
7.3 Europe Recombinant Vector Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Vector Vaccines by Country
8.1.1 Middle East & Africa Recombinant Vector Vaccines Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Vector Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Vector Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Vector Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Vector Vaccines
10.3 Manufacturing Process Analysis of Recombinant Vector Vaccines
10.4 Industry Chain Structure of Recombinant Vector Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Vector Vaccines Distributors
11.3 Recombinant Vector Vaccines Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT VECTOR VACCINES BY GEOGRAPHIC REGION
12.1 Global Recombinant Vector Vaccines Market Size Forecast by Region
12.1.1 Global Recombinant Vector Vaccines Forecast by Region (2026-2031)
12.1.2 Global Recombinant Vector Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Vector Vaccines Forecast by Type (2026-2031)
12.7 Global Recombinant Vector Vaccines Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 SANOFI PASTEUR S.A.
13.1.1 SANOFI PASTEUR S.A. Company Information
13.1.2 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolios and Specifications
13.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 SANOFI PASTEUR S.A. Main Business Overview
13.1.5 SANOFI PASTEUR S.A. Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Recombinant Vector Vaccines Product Portfolios and Specifications
13.2.3 Novartis Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Recombinant Vector Vaccines Product Portfolios and Specifications
13.3.3 GSK Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 CNBG
13.4.1 CNBG Company Information
13.4.2 CNBG Recombinant Vector Vaccines Product Portfolios and Specifications
13.4.3 CNBG Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 CNBG Main Business Overview
13.4.5 CNBG Latest Developments
13.5 ChengDa Bio
13.5.1 ChengDa Bio Company Information
13.5.2 ChengDa Bio Recombinant Vector Vaccines Product Portfolios and Specifications
13.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 ChengDa Bio Main Business Overview
13.5.5 ChengDa Bio Latest Developments
13.6 Changsheng Life
13.6.1 Changsheng Life Company Information
13.6.2 Changsheng Life Recombinant Vector Vaccines Product Portfolios and Specifications
13.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Changsheng Life Main Business Overview
13.6.5 Changsheng Life Latest Developments
13.7 Zhifei
13.7.1 Zhifei Company Information
13.7.2 Zhifei Recombinant Vector Vaccines Product Portfolios and Specifications
13.7.3 Zhifei Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Zhifei Main Business Overview
13.7.5 Zhifei Latest Developments
13.8 SINOVAC BIOTECH
13.8.1 SINOVAC BIOTECH Company Information
13.8.2 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolios and Specifications
13.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 SINOVAC BIOTECH Main Business Overview
13.8.5 SINOVAC BIOTECH Latest Developments
13.9 NuoCheng Bio
13.9.1 NuoCheng Bio Company Information
13.9.2 NuoCheng Bio Recombinant Vector Vaccines Product Portfolios and Specifications
13.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 NuoCheng Bio Main Business Overview
13.9.5 NuoCheng Bio Latest Developments
13.10 Hualan Bio
13.10.1 Hualan Bio Company Information
13.10.2 Hualan Bio Recombinant Vector Vaccines Product Portfolios and Specifications
13.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Hualan Bio Main Business Overview
13.10.5 Hualan Bio Latest Developments
13.11 Kangtai
13.11.1 Kangtai Company Information
13.11.2 Kangtai Recombinant Vector Vaccines Product Portfolios and Specifications
13.11.3 Kangtai Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Kangtai Main Business Overview
13.11.5 Kangtai Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Vector Vaccines Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Vector Vaccines by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Vector Vaccines by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Vector Vaccines Segment by Type
2.2.1 Varicella
2.2.2 Influenza
2.2.3 Hepatitis
2.2.4 Pertussis, Diphtheria, tetanus
2.2.5 Pneumococcal
2.2.6 Others
2.3 Recombinant Vector Vaccines Sales by Type
2.3.1 Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
2.3.2 Global Recombinant Vector Vaccines Revenue and Market Share by Type (2020-2025)
2.3.3 Global Recombinant Vector Vaccines Sale Price by Type (2020-2025)
2.4 Recombinant Vector Vaccines Segment by Application
2.4.1 For Adult
2.4.2 For Child
2.5 Recombinant Vector Vaccines Sales by Application
2.5.1 Global Recombinant Vector Vaccines Sale Market Share by Application (2020-2025)
2.5.2 Global Recombinant Vector Vaccines Revenue and Market Share by Application (2020-2025)
2.5.3 Global Recombinant Vector Vaccines Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Recombinant Vector Vaccines Breakdown Data by Company
3.1.1 Global Recombinant Vector Vaccines Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Vector Vaccines Sales Market Share by Company (2020-2025)
3.2 Global Recombinant Vector Vaccines Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Vector Vaccines Revenue by Company (2020-2025)
3.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global Recombinant Vector Vaccines Sale Price by Company
3.4 Key Manufacturers Recombinant Vector Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Vector Vaccines Product Location Distribution
3.4.2 Players Recombinant Vector Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RECOMBINANT VECTOR VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Vector Vaccines Market Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Vector Vaccines Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Vector Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Vector Vaccines Market Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Vector Vaccines Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Vector Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Vector Vaccines Sales Growth
4.4 APAC Recombinant Vector Vaccines Sales Growth
4.5 Europe Recombinant Vector Vaccines Sales Growth
4.6 Middle East & Africa Recombinant Vector Vaccines Sales Growth
5 AMERICAS
5.1 Americas Recombinant Vector Vaccines Sales by Country
5.1.1 Americas Recombinant Vector Vaccines Sales by Country (2020-2025)
5.1.2 Americas Recombinant Vector Vaccines Revenue by Country (2020-2025)
5.2 Americas Recombinant Vector Vaccines Sales by Type (2020-2025)
5.3 Americas Recombinant Vector Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Vector Vaccines Sales by Region
6.1.1 APAC Recombinant Vector Vaccines Sales by Region (2020-2025)
6.1.2 APAC Recombinant Vector Vaccines Revenue by Region (2020-2025)
6.2 APAC Recombinant Vector Vaccines Sales by Type (2020-2025)
6.3 APAC Recombinant Vector Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Vector Vaccines by Country
7.1.1 Europe Recombinant Vector Vaccines Sales by Country (2020-2025)
7.1.2 Europe Recombinant Vector Vaccines Revenue by Country (2020-2025)
7.2 Europe Recombinant Vector Vaccines Sales by Type (2020-2025)
7.3 Europe Recombinant Vector Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Vector Vaccines by Country
8.1.1 Middle East & Africa Recombinant Vector Vaccines Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Vector Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Vector Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Vector Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Vector Vaccines
10.3 Manufacturing Process Analysis of Recombinant Vector Vaccines
10.4 Industry Chain Structure of Recombinant Vector Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Vector Vaccines Distributors
11.3 Recombinant Vector Vaccines Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT VECTOR VACCINES BY GEOGRAPHIC REGION
12.1 Global Recombinant Vector Vaccines Market Size Forecast by Region
12.1.1 Global Recombinant Vector Vaccines Forecast by Region (2026-2031)
12.1.2 Global Recombinant Vector Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Vector Vaccines Forecast by Type (2026-2031)
12.7 Global Recombinant Vector Vaccines Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 SANOFI PASTEUR S.A.
13.1.1 SANOFI PASTEUR S.A. Company Information
13.1.2 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolios and Specifications
13.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 SANOFI PASTEUR S.A. Main Business Overview
13.1.5 SANOFI PASTEUR S.A. Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Recombinant Vector Vaccines Product Portfolios and Specifications
13.2.3 Novartis Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Recombinant Vector Vaccines Product Portfolios and Specifications
13.3.3 GSK Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 CNBG
13.4.1 CNBG Company Information
13.4.2 CNBG Recombinant Vector Vaccines Product Portfolios and Specifications
13.4.3 CNBG Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 CNBG Main Business Overview
13.4.5 CNBG Latest Developments
13.5 ChengDa Bio
13.5.1 ChengDa Bio Company Information
13.5.2 ChengDa Bio Recombinant Vector Vaccines Product Portfolios and Specifications
13.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 ChengDa Bio Main Business Overview
13.5.5 ChengDa Bio Latest Developments
13.6 Changsheng Life
13.6.1 Changsheng Life Company Information
13.6.2 Changsheng Life Recombinant Vector Vaccines Product Portfolios and Specifications
13.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Changsheng Life Main Business Overview
13.6.5 Changsheng Life Latest Developments
13.7 Zhifei
13.7.1 Zhifei Company Information
13.7.2 Zhifei Recombinant Vector Vaccines Product Portfolios and Specifications
13.7.3 Zhifei Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Zhifei Main Business Overview
13.7.5 Zhifei Latest Developments
13.8 SINOVAC BIOTECH
13.8.1 SINOVAC BIOTECH Company Information
13.8.2 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolios and Specifications
13.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 SINOVAC BIOTECH Main Business Overview
13.8.5 SINOVAC BIOTECH Latest Developments
13.9 NuoCheng Bio
13.9.1 NuoCheng Bio Company Information
13.9.2 NuoCheng Bio Recombinant Vector Vaccines Product Portfolios and Specifications
13.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 NuoCheng Bio Main Business Overview
13.9.5 NuoCheng Bio Latest Developments
13.10 Hualan Bio
13.10.1 Hualan Bio Company Information
13.10.2 Hualan Bio Recombinant Vector Vaccines Product Portfolios and Specifications
13.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Hualan Bio Main Business Overview
13.10.5 Hualan Bio Latest Developments
13.11 Kangtai
13.11.1 Kangtai Company Information
13.11.2 Kangtai Recombinant Vector Vaccines Product Portfolios and Specifications
13.11.3 Kangtai Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Kangtai Main Business Overview
13.11.5 Kangtai Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Recombinant Vector Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Recombinant Vector Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Varicella
Table 4. Major Players of Influenza
Table 5. Major Players of Hepatitis
Table 6. Major Players of Pertussis, Diphtheria, tetanus
Table 7. Major Players of Pneumococcal
Table 8. Major Players of Others
Table 9. Global Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 10. Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Table 11. Global Recombinant Vector Vaccines Revenue by Type (2020-2025) & ($ million)
Table 12. Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2025)
Table 13. Global Recombinant Vector Vaccines Sale Price by Type (2020-2025) & (USD/Dose)
Table 14. Global Recombinant Vector Vaccines Sale by Application (2020-2025) & (K Doses)
Table 15. Global Recombinant Vector Vaccines Sale Market Share by Application (2020-2025)
Table 16. Global Recombinant Vector Vaccines Revenue by Application (2020-2025) & ($ million)
Table 17. Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2025)
Table 18. Global Recombinant Vector Vaccines Sale Price by Application (2020-2025) & (USD/Dose)
Table 19. Global Recombinant Vector Vaccines Sales by Company (2020-2025) & (K Doses)
Table 20. Global Recombinant Vector Vaccines Sales Market Share by Company (2020-2025)
Table 21. Global Recombinant Vector Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Recombinant Vector Vaccines Revenue Market Share by Company (2020-2025)
Table 23. Global Recombinant Vector Vaccines Sale Price by Company (2020-2025) & (USD/Dose)
Table 24. Key Manufacturers Recombinant Vector Vaccines Producing Area Distribution and Sales Area
Table 25. Players Recombinant Vector Vaccines Products Offered
Table 26. Recombinant Vector Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Recombinant Vector Vaccines Sales by Geographic Region (2020-2025) & (K Doses)
Table 30. Global Recombinant Vector Vaccines Sales Market Share Geographic Region (2020-2025)
Table 31. Global Recombinant Vector Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Recombinant Vector Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Recombinant Vector Vaccines Sales by Country/Region (2020-2025) & (K Doses)
Table 34. Global Recombinant Vector Vaccines Sales Market Share by Country/Region (2020-2025)
Table 35. Global Recombinant Vector Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Recombinant Vector Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Recombinant Vector Vaccines Sales by Country (2020-2025) & (K Doses)
Table 38. Americas Recombinant Vector Vaccines Sales Market Share by Country (2020-2025)
Table 39. Americas Recombinant Vector Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 41. Americas Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 42. APAC Recombinant Vector Vaccines Sales by Region (2020-2025) & (K Doses)
Table 43. APAC Recombinant Vector Vaccines Sales Market Share by Region (2020-2025)
Table 44. APAC Recombinant Vector Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 46. APAC Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 47. Europe Recombinant Vector Vaccines Sales by Country (2020-2025) & (K Doses)
Table 48. Europe Recombinant Vector Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 50. Europe Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 51. Middle East & Africa Recombinant Vector Vaccines Sales by Country (2020-2025) & (K Doses)
Table 52. Middle East & Africa Recombinant Vector Vaccines Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 54. Middle East & Africa Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 55. Key Market Drivers & Growth Opportunities of Recombinant Vector Vaccines
Table 56. Key Market Challenges & Risks of Recombinant Vector Vaccines
Table 57. Key Industry Trends of Recombinant Vector Vaccines
Table 58. Recombinant Vector Vaccines Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Recombinant Vector Vaccines Distributors List
Table 61. Recombinant Vector Vaccines Customer List
Table 62. Global Recombinant Vector Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 63. Global Recombinant Vector Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Recombinant Vector Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 65. Americas Recombinant Vector Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Recombinant Vector Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 67. APAC Recombinant Vector Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Recombinant Vector Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 69. Europe Recombinant Vector Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Recombinant Vector Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 71. Middle East & Africa Recombinant Vector Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Recombinant Vector Vaccines Sales Forecast by Type (2026-2031) & (K Doses)
Table 73. Global Recombinant Vector Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Recombinant Vector Vaccines Sales Forecast by Application (2026-2031) & (K Doses)
Table 75. Global Recombinant Vector Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. SANOFI PASTEUR S.A. Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 77. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolios and Specifications
Table 78. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 79. SANOFI PASTEUR S.A. Main Business
Table 80. SANOFI PASTEUR S.A. Latest Developments
Table 81. Novartis Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis Recombinant Vector Vaccines Product Portfolios and Specifications
Table 83. Novartis Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 84. Novartis Main Business
Table 85. Novartis Latest Developments
Table 86. GSK Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 87. GSK Recombinant Vector Vaccines Product Portfolios and Specifications
Table 88. GSK Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 89. GSK Main Business
Table 90. GSK Latest Developments
Table 91. CNBG Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 92. CNBG Recombinant Vector Vaccines Product Portfolios and Specifications
Table 93. CNBG Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 94. CNBG Main Business
Table 95. CNBG Latest Developments
Table 96. ChengDa Bio Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 97. ChengDa Bio Recombinant Vector Vaccines Product Portfolios and Specifications
Table 98. ChengDa Bio Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 99. ChengDa Bio Main Business
Table 100. ChengDa Bio Latest Developments
Table 101. Changsheng Life Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 102. Changsheng Life Recombinant Vector Vaccines Product Portfolios and Specifications
Table 103. Changsheng Life Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 104. Changsheng Life Main Business
Table 105. Changsheng Life Latest Developments
Table 106. Zhifei Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 107. Zhifei Recombinant Vector Vaccines Product Portfolios and Specifications
Table 108. Zhifei Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 109. Zhifei Main Business
Table 110. Zhifei Latest Developments
Table 111. SINOVAC BIOTECH Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 112. SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolios and Specifications
Table 113. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 114. SINOVAC BIOTECH Main Business
Table 115. SINOVAC BIOTECH Latest Developments
Table 116. NuoCheng Bio Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 117. NuoCheng Bio Recombinant Vector Vaccines Product Portfolios and Specifications
Table 118. NuoCheng Bio Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 119. NuoCheng Bio Main Business
Table 120. NuoCheng Bio Latest Developments
Table 121. Hualan Bio Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 122. Hualan Bio Recombinant Vector Vaccines Product Portfolios and Specifications
Table 123. Hualan Bio Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 124. Hualan Bio Main Business
Table 125. Hualan Bio Latest Developments
Table 126. Kangtai Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 127. Kangtai Recombinant Vector Vaccines Product Portfolios and Specifications
Table 128. Kangtai Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 129. Kangtai Main Business
Table 130. Kangtai Latest Developments
Table 1. Recombinant Vector Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Recombinant Vector Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Varicella
Table 4. Major Players of Influenza
Table 5. Major Players of Hepatitis
Table 6. Major Players of Pertussis, Diphtheria, tetanus
Table 7. Major Players of Pneumococcal
Table 8. Major Players of Others
Table 9. Global Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 10. Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Table 11. Global Recombinant Vector Vaccines Revenue by Type (2020-2025) & ($ million)
Table 12. Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2025)
Table 13. Global Recombinant Vector Vaccines Sale Price by Type (2020-2025) & (USD/Dose)
Table 14. Global Recombinant Vector Vaccines Sale by Application (2020-2025) & (K Doses)
Table 15. Global Recombinant Vector Vaccines Sale Market Share by Application (2020-2025)
Table 16. Global Recombinant Vector Vaccines Revenue by Application (2020-2025) & ($ million)
Table 17. Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2025)
Table 18. Global Recombinant Vector Vaccines Sale Price by Application (2020-2025) & (USD/Dose)
Table 19. Global Recombinant Vector Vaccines Sales by Company (2020-2025) & (K Doses)
Table 20. Global Recombinant Vector Vaccines Sales Market Share by Company (2020-2025)
Table 21. Global Recombinant Vector Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Recombinant Vector Vaccines Revenue Market Share by Company (2020-2025)
Table 23. Global Recombinant Vector Vaccines Sale Price by Company (2020-2025) & (USD/Dose)
Table 24. Key Manufacturers Recombinant Vector Vaccines Producing Area Distribution and Sales Area
Table 25. Players Recombinant Vector Vaccines Products Offered
Table 26. Recombinant Vector Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Recombinant Vector Vaccines Sales by Geographic Region (2020-2025) & (K Doses)
Table 30. Global Recombinant Vector Vaccines Sales Market Share Geographic Region (2020-2025)
Table 31. Global Recombinant Vector Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Recombinant Vector Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Recombinant Vector Vaccines Sales by Country/Region (2020-2025) & (K Doses)
Table 34. Global Recombinant Vector Vaccines Sales Market Share by Country/Region (2020-2025)
Table 35. Global Recombinant Vector Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Recombinant Vector Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Recombinant Vector Vaccines Sales by Country (2020-2025) & (K Doses)
Table 38. Americas Recombinant Vector Vaccines Sales Market Share by Country (2020-2025)
Table 39. Americas Recombinant Vector Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 41. Americas Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 42. APAC Recombinant Vector Vaccines Sales by Region (2020-2025) & (K Doses)
Table 43. APAC Recombinant Vector Vaccines Sales Market Share by Region (2020-2025)
Table 44. APAC Recombinant Vector Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 46. APAC Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 47. Europe Recombinant Vector Vaccines Sales by Country (2020-2025) & (K Doses)
Table 48. Europe Recombinant Vector Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 50. Europe Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 51. Middle East & Africa Recombinant Vector Vaccines Sales by Country (2020-2025) & (K Doses)
Table 52. Middle East & Africa Recombinant Vector Vaccines Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Recombinant Vector Vaccines Sales by Type (2020-2025) & (K Doses)
Table 54. Middle East & Africa Recombinant Vector Vaccines Sales by Application (2020-2025) & (K Doses)
Table 55. Key Market Drivers & Growth Opportunities of Recombinant Vector Vaccines
Table 56. Key Market Challenges & Risks of Recombinant Vector Vaccines
Table 57. Key Industry Trends of Recombinant Vector Vaccines
Table 58. Recombinant Vector Vaccines Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Recombinant Vector Vaccines Distributors List
Table 61. Recombinant Vector Vaccines Customer List
Table 62. Global Recombinant Vector Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 63. Global Recombinant Vector Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Recombinant Vector Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 65. Americas Recombinant Vector Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Recombinant Vector Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 67. APAC Recombinant Vector Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Recombinant Vector Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 69. Europe Recombinant Vector Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Recombinant Vector Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 71. Middle East & Africa Recombinant Vector Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Recombinant Vector Vaccines Sales Forecast by Type (2026-2031) & (K Doses)
Table 73. Global Recombinant Vector Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Recombinant Vector Vaccines Sales Forecast by Application (2026-2031) & (K Doses)
Table 75. Global Recombinant Vector Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. SANOFI PASTEUR S.A. Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 77. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolios and Specifications
Table 78. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 79. SANOFI PASTEUR S.A. Main Business
Table 80. SANOFI PASTEUR S.A. Latest Developments
Table 81. Novartis Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis Recombinant Vector Vaccines Product Portfolios and Specifications
Table 83. Novartis Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 84. Novartis Main Business
Table 85. Novartis Latest Developments
Table 86. GSK Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 87. GSK Recombinant Vector Vaccines Product Portfolios and Specifications
Table 88. GSK Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 89. GSK Main Business
Table 90. GSK Latest Developments
Table 91. CNBG Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 92. CNBG Recombinant Vector Vaccines Product Portfolios and Specifications
Table 93. CNBG Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 94. CNBG Main Business
Table 95. CNBG Latest Developments
Table 96. ChengDa Bio Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 97. ChengDa Bio Recombinant Vector Vaccines Product Portfolios and Specifications
Table 98. ChengDa Bio Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 99. ChengDa Bio Main Business
Table 100. ChengDa Bio Latest Developments
Table 101. Changsheng Life Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 102. Changsheng Life Recombinant Vector Vaccines Product Portfolios and Specifications
Table 103. Changsheng Life Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 104. Changsheng Life Main Business
Table 105. Changsheng Life Latest Developments
Table 106. Zhifei Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 107. Zhifei Recombinant Vector Vaccines Product Portfolios and Specifications
Table 108. Zhifei Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 109. Zhifei Main Business
Table 110. Zhifei Latest Developments
Table 111. SINOVAC BIOTECH Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 112. SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolios and Specifications
Table 113. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 114. SINOVAC BIOTECH Main Business
Table 115. SINOVAC BIOTECH Latest Developments
Table 116. NuoCheng Bio Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 117. NuoCheng Bio Recombinant Vector Vaccines Product Portfolios and Specifications
Table 118. NuoCheng Bio Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 119. NuoCheng Bio Main Business
Table 120. NuoCheng Bio Latest Developments
Table 121. Hualan Bio Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 122. Hualan Bio Recombinant Vector Vaccines Product Portfolios and Specifications
Table 123. Hualan Bio Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 124. Hualan Bio Main Business
Table 125. Hualan Bio Latest Developments
Table 126. Kangtai Basic Information, Recombinant Vector Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 127. Kangtai Recombinant Vector Vaccines Product Portfolios and Specifications
Table 128. Kangtai Recombinant Vector Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 129. Kangtai Main Business
Table 130. Kangtai Latest Developments
LIST OF FIGURES
Figure 1. Picture of Recombinant Vector Vaccines
Figure 2. Recombinant Vector Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Vector Vaccines Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Recombinant Vector Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Recombinant Vector Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Recombinant Vector Vaccines Sales Market Share by Country/Region (2024)
Figure 10. Recombinant Vector Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Varicella
Figure 12. Product Picture of Influenza
Figure 13. Product Picture of Hepatitis
Figure 14. Product Picture of Pertussis, Diphtheria, tetanus
Figure 15. Product Picture of Pneumococcal
Figure 16. Product Picture of Others
Figure 17. Global Recombinant Vector Vaccines Sales Market Share by Type in 2025
Figure 18. Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2025)
Figure 19. Recombinant Vector Vaccines Consumed in For Adult
Figure 20. Global Recombinant Vector Vaccines Market: For Adult (2020-2025) & (K Doses)
Figure 21. Recombinant Vector Vaccines Consumed in For Child
Figure 22. Global Recombinant Vector Vaccines Market: For Child (2020-2025) & (K Doses)
Figure 23. Global Recombinant Vector Vaccines Sale Market Share by Application (2024)
Figure 24. Global Recombinant Vector Vaccines Revenue Market Share by Application in 2025
Figure 25. Recombinant Vector Vaccines Sales by Company in 2025 (K Doses)
Figure 26. Global Recombinant Vector Vaccines Sales Market Share by Company in 2025
Figure 27. Recombinant Vector Vaccines Revenue by Company in 2025 ($ millions)
Figure 28. Global Recombinant Vector Vaccines Revenue Market Share by Company in 2025
Figure 29. Global Recombinant Vector Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Recombinant Vector Vaccines Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 32. Americas Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 33. APAC Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 34. APAC Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 35. Europe Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 36. Europe Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 38. Middle East & Africa Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 39. Americas Recombinant Vector Vaccines Sales Market Share by Country in 2025
Figure 40. Americas Recombinant Vector Vaccines Revenue Market Share by Country (2020-2025)
Figure 41. Americas Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 42. Americas Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 43. United States Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Recombinant Vector Vaccines Sales Market Share by Region in 2025
Figure 48. APAC Recombinant Vector Vaccines Revenue Market Share by Region (2020-2025)
Figure 49. APAC Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 50. APAC Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 51. China Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. India Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Recombinant Vector Vaccines Sales Market Share by Country in 2025
Figure 59. Europe Recombinant Vector Vaccines Revenue Market Share by Country (2020-2025)
Figure 60. Europe Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 61. Europe Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 62. Germany Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. France Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 70. Egypt Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Recombinant Vector Vaccines in 2025
Figure 76. Manufacturing Process Analysis of Recombinant Vector Vaccines
Figure 77. Industry Chain Structure of Recombinant Vector Vaccines
Figure 78. Channels of Distribution
Figure 79. Global Recombinant Vector Vaccines Sales Market Forecast by Region (2026-2031)
Figure 80. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Recombinant Vector Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Recombinant Vector Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Recombinant Vector Vaccines
Figure 2. Recombinant Vector Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Vector Vaccines Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Recombinant Vector Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Recombinant Vector Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Recombinant Vector Vaccines Sales Market Share by Country/Region (2024)
Figure 10. Recombinant Vector Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Varicella
Figure 12. Product Picture of Influenza
Figure 13. Product Picture of Hepatitis
Figure 14. Product Picture of Pertussis, Diphtheria, tetanus
Figure 15. Product Picture of Pneumococcal
Figure 16. Product Picture of Others
Figure 17. Global Recombinant Vector Vaccines Sales Market Share by Type in 2025
Figure 18. Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2025)
Figure 19. Recombinant Vector Vaccines Consumed in For Adult
Figure 20. Global Recombinant Vector Vaccines Market: For Adult (2020-2025) & (K Doses)
Figure 21. Recombinant Vector Vaccines Consumed in For Child
Figure 22. Global Recombinant Vector Vaccines Market: For Child (2020-2025) & (K Doses)
Figure 23. Global Recombinant Vector Vaccines Sale Market Share by Application (2024)
Figure 24. Global Recombinant Vector Vaccines Revenue Market Share by Application in 2025
Figure 25. Recombinant Vector Vaccines Sales by Company in 2025 (K Doses)
Figure 26. Global Recombinant Vector Vaccines Sales Market Share by Company in 2025
Figure 27. Recombinant Vector Vaccines Revenue by Company in 2025 ($ millions)
Figure 28. Global Recombinant Vector Vaccines Revenue Market Share by Company in 2025
Figure 29. Global Recombinant Vector Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Recombinant Vector Vaccines Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 32. Americas Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 33. APAC Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 34. APAC Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 35. Europe Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 36. Europe Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Recombinant Vector Vaccines Sales 2020-2025 (K Doses)
Figure 38. Middle East & Africa Recombinant Vector Vaccines Revenue 2020-2025 ($ millions)
Figure 39. Americas Recombinant Vector Vaccines Sales Market Share by Country in 2025
Figure 40. Americas Recombinant Vector Vaccines Revenue Market Share by Country (2020-2025)
Figure 41. Americas Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 42. Americas Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 43. United States Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Recombinant Vector Vaccines Sales Market Share by Region in 2025
Figure 48. APAC Recombinant Vector Vaccines Revenue Market Share by Region (2020-2025)
Figure 49. APAC Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 50. APAC Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 51. China Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. India Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Recombinant Vector Vaccines Sales Market Share by Country in 2025
Figure 59. Europe Recombinant Vector Vaccines Revenue Market Share by Country (2020-2025)
Figure 60. Europe Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 61. Europe Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 62. Germany Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. France Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Recombinant Vector Vaccines Sales Market Share by Application (2020-2025)
Figure 70. Egypt Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Recombinant Vector Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Recombinant Vector Vaccines in 2025
Figure 76. Manufacturing Process Analysis of Recombinant Vector Vaccines
Figure 77. Industry Chain Structure of Recombinant Vector Vaccines
Figure 78. Channels of Distribution
Figure 79. Global Recombinant Vector Vaccines Sales Market Forecast by Region (2026-2031)
Figure 80. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Recombinant Vector Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Recombinant Vector Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Viral Vector Vaccines Market Growth 2025-2031
US$ 3,660.00
December 2025
102 pages
